In addition to the FDA-approved approach to treat some BRCA1-deficient breast and ovary cancers with PARP inhibitors, these drugs have emerged as a potential cure that acts directly on hematopoietic cancers. The gene discussed is PARP1; the disease is hematopoietic and lymphoid cell neoplasm.